NIH-funded research NIH-funded research

Altering tiny eye-cell particles to protect and restore the aging retina

Official title: Modulation of Exosome Release for Functional Restoration in Age-related Retinal Disorders

Funded at Mc Laughlin Research Institute · NIH-11350892 · Data updated 2026-11-12

The team is testing whether changing tiny particles released by retinal support cells can help protect or restore vision for people with age-related macular degeneration.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionMc Laughlin Research Institute
NIH-funded
Lab location1 site (Great Falls, United States)
Project startJanuary 1, 2024
Project endDecember 31, 2028
Funding year2026
Award (this year)$317,636
NIH project number5P20GM152335-03
Project IDNIH-11350892 on NIH RePORTER

Who could benefit from this research

Could help

People with age-related macular degeneration—especially those with early or intermediate disease linked to RPE dysfunction—would be the most relevant patient group.

Less likely to help

People whose vision loss is due to non-AMD conditions or those with very advanced, irreversible retinal atrophy are unlikely to benefit directly from this preclinical work.

What this research studies

As someone with AMD, I would hear that researchers are studying tiny packages called exosomes that retinal support cells (RPE) release and that these may harm the outer blood-retina barrier. They will stress RPE cells in lab dishes to see how exosome release affects cell connections and deposit formation, and will change exosome release in mouse models that mimic AMD. The team will look for signs of preserved RPE and photoreceptor health and less barrier breakdown as a step toward new therapies.

Why it matters

Potential benefit: If successful, this work could point to treatments that slow or reverse RPE damage and help preserve vision in AMD.

How similar studies have gone: This is largely a preclinical and novel approach: some laboratory studies suggest exosomes influence retinal health, but clinical success with this strategy has not yet been shown.

Where this research is happening

  • Mc Laughlin Research Institute
    Great Falls, United States
    Active

Researchers

  • Principal investigator: Klingeborn, Mikael — Mc Laughlin Research Institute
  • Study coordinator: Klingeborn, Mikael

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.